Prof Wee Joo Chng speaks to ecancer about the clinical value of maintenance in multiple myeloma. Initially, he mentions the maintenance treatments he recommends for multiple myeloma patients.

Prof Chng also gives different regimen recommendation for high-risk cytogenetics patients. He discusses the phase 3 TOURMALINE-MM4 trial investigating ixazomib vs placebo as post-induction maintenance therapy in newly diagnosed multiple myeloma (NDMM) patients not undergoing autologous stem cell transplant (ASCT).

Prof Chng also talks about the measurable residual disease (MRD) evaluation during ixazomib (IXA) maintenance in newly diagnosed multiple myeloma (NDMM). In the end, he discusses what patient profile should receive maintenance treatments (for both the transplant eligible and ineligible) and the impact of the TOURMALINE MM3 and MM4 data in clinical practice.

This programme has been supported by an unrestricted educational grant from Takeda.